<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00837863</url>
  </required_header>
  <id_info>
    <org_study_id>0001194</org_study_id>
    <nct_id>NCT00837863</nct_id>
  </id_info>
  <brief_title>Study of Weekly ALTU-238 Compared With Daily Nutropin AQ in Prepubertal Children With Growth Hormone Deficiency</brief_title>
  <official_title>A Twelve Month, Phase II, Randomized, Open-Label, Multi-Center, Dose-Ranging Study of Weekly ALTU-238 (Somatropin) as Compared With Daily Nutropin AQ (Somatropin) in Prepubertal Children With Growth Hormone Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Altus Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Altus Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety and effectiveness of ALTU-238 in the
      treatment of children with growth hormone deficiency who have not yet reached puberty who
      lack the normal ability to make growth hormone themselves. This study will also test if
      ALTU-238 works as a weekly treatment.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2009</start_date>
  <primary_completion_date type="Anticipated">September 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in annualized height velocity from pre-treatment to the first 26 weeks of treatment</measure>
    <time_frame>26 Weeks</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Growth Hormone Deficiency</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALTU-238</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALTU-238</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALTU-238</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nutropin AQ</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Somatropin</intervention_name>
    <description>ALTU-238 0.3 mg/kg daily</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Somatropin</intervention_name>
    <description>ALTU-238 0.6 mg/kg daily</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Somatropin</intervention_name>
    <description>ALTU-238 0.9 mg/kg daily</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Somatropin</intervention_name>
    <description>Nutropin AQ 0.043 mg/kg daily</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Assent of subject, if applicable, and written informed consent of parent or legal
             guardian

          2. Diagnosis of GHD as defined by a maximum stimulated GH &lt; 7 ng/mL (μg/L) on two
             stimulation tests (using any two distinct agents from the following list: arginine,
             L-dopa, clonidine, insulin, or glucagon); if two documented historical tests are not
             available,test(s) must be performed during Screening period

          3. Available results from one or more historical CT or MRI scans of the head obtained at
             or following the diagnosis of GHD

          4. Chronologic age at Screening of 3 to 13 years (inclusive) for boys and 3 to 12
             years(inclusive) for girls

          5. Bone age at Screening of ≤ 11 years for boys and ≤ 10 years for girls

          6. Pre-pubertal at Screening (Tanner stage 1 for both breast/genitalia and pubic hair

          7. For subjects with idiopathic GHD, a Screening height SDS ≤ -2.0 (standardized for
             chronologic age and sex) there is no height SDS requirement if the subject has organic
             GHD (as defined by a CNS lesion or insult on a historical CT or MRI scan)

          8. Pre-treatment annualized height velocity ≤ median (50th percentile) for chronologic
             age and sex (based on values for delayed maturers provided in Appendix 4), utilizing
             Screening height and height obtained 52 ± 13 weeks (i.e. 39 to 65 weeks) prior to
             Screening

          9. Screening IGF-1 SDS for chronologic age and sex &lt; -1

         10. If on thyroid hormone replacement therapy, the dose must be stable for at least 6
             weeks prior to Screening and the free thyroxine level (T4), TSH, and cortisol must be
             within the normal range at the Screening visit

        Exclusion Criteria:

          1. History of any prior rhGH, rhIGF-1, or sex steroid treatment

          2. History of treatment with any medications that may affect growth

          3. Evidence of active intracranial neoplasm per recent serial CT or MRI scans of the head
             or other criteria

          4. Surgery/chemotherapy/radiation therapy for intracranial neoplasm within the prior 52
             weeks

          5. Any history of non-intracranial neoplasm

          6. History of or active benign intracranial hypertension

          7. High-dose chronic systemic corticosteroid treatment (oral or injected) within prior 13
             weeks

          8. Acute or severe illness within prior 26 weeks

          9. History of diabetes mellitus, anorexia nervosa, cystic fibrosis, chronic severe kidney
             or liver disease, chronic infectious disease, inborn errors of metabolism, chromosomal
             disorders, intrauterine growth retardation, or other childhood disease associated with
             growth failure

         10. History of congenital syndromes associated with abnormal growth, including Turner
             syndrome, Noonan syndrome, Prader-Willi syndrome, etc.

         11. History of severe associated pathology affecting growth, including
             malnutrition,malabsorption, or bone dysplasia

         12. History of autoimmune disease

         13. Serum ALT or AST ≥ 1.5X ULN

         14. Participation in another clinical trial or treatment with any investigational agent
             (drug or biologic) within 30 days prior to Baseline if the half-life of the agent is
             known to be ≤ 6 days or within 6 weeks prior to Baseline if the half-life is &gt; 6 days
             or not known

         15. History of any allergic or abnormal reaction to any of the components of the study
             drugs

         16. Any previous or ongoing clinically significant illness, PE findings, or laboratory
             abnormality that, in the opinion of the Investigator or the Medical Monitor, could
             prevent the subject from completing the protocol-specified requirements successfully

         17. Poor likelihood, in the Investigator's opinion, that the subject will comply with
             protocol requirements (e.g., uncooperative attitude, inability to return for follow-up
             visits, history of medical noncompliance) and/or poor likelihood of completing the
             study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>13 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dr. Kenneth Attie, Medical Monitor</last_name>
    <phone>781-373-6481</phone>
    <email>kattie@altus.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Stephen Kemp</last_name>
    </contact>
    <investigator>
      <last_name>Dr Stephen Kemp</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Jorge Daaboul</last_name>
      <phone>407-650-7210</phone>
    </contact>
    <investigator>
      <last_name>Dr. Jorge Daaboul</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baystate Medical Centre</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01199</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Edward Reiter</last_name>
      <phone>413-794-5060</phone>
    </contact>
    <investigator>
      <last_name>Dr Edward Reiter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMass Memorial Medical Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Leslie Soyka</last_name>
      <phone>508-856-6289</phone>
    </contact>
    <investigator>
      <last_name>Dr. Leslie Soyka</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Finen Ugrasbul</last_name>
      <phone>816-234-3973</phone>
    </contact>
    <investigator>
      <last_name>Dr. Finen Ugrasbul</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Morristown Memorial Hospital</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Lawrence Silverman</last_name>
      <phone>973-971-6340</phone>
    </contact>
    <investigator>
      <last_name>Dr. Lawrence Silverman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Schneider Children's Hospital</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Phyllis Speiser</last_name>
      <phone>718-470-3290</phone>
    </contact>
    <investigator>
      <last_name>Dr. Phyllis Speiser</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Medical Centre</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Susan Rose</last_name>
      <phone>513-636-4744</phone>
    </contact>
    <investigator>
      <last_name>Dr Susan Rose</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cook Children's Hospital</name>
      <address>
        <city>Ft. Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Paul Thornton</last_name>
      <phone>682-885-7960</phone>
    </contact>
    <investigator>
      <last_name>Dr. Paul Thornton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Patricia Fetchner</last_name>
    </contact>
    <investigator>
      <last_name>Dr Patricia Fetchner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Gad Kletter</last_name>
      <phone>206-215-2700</phone>
    </contact>
    <investigator>
      <last_name>Dr. Gad Kletter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2009</study_first_submitted>
  <study_first_submitted_qc>February 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2009</study_first_posted>
  <last_update_submitted>May 6, 2009</last_update_submitted>
  <last_update_submitted_qc>May 6, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 7, 2009</last_update_posted>
  <responsible_party>
    <name_title>Kenneth Attie, M.D.</name_title>
    <organization>Altus Pharmaceuticals</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endocrine System Diseases</mesh_term>
    <mesh_term>Dwarfism, Pituitary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

